Dyslipoproteinemia and coronary disease

被引:2
|
作者
Raos, V
Strujuc, BJ
机构
[1] Univ Zagreb, Dubrava Univ Hosp, Dept Internal Med, Zagreb 10000, Croatia
[2] Univ Zagreb, Dubrava Univ Hosp, Dept Cardiol, Zagreb 10000, Croatia
关键词
D O I
10.1177/000331970205300509
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Dyslipoproteinemia is involved in the origin of arteriosclerosis by changing the architecture of the coronary artery wall and therefore represents an important factor in the development of coronary artery disease (CAD), High-density lipoprotein (HDL) and apolipoprotein-A1 (Apo A(1)) serve as protection against the origin and development of coronary obstructive disease. The aims of this study were to evaluate the relations among the plasma lipids, their fraction Apo A(1), HDL, and positive coronary arteriography, and to estimate their importance as markers of the degree of coronary lesions, The study included 101 subjects, 77 men and 24 women, aged 35 to 75 years, mean age = 55.7 years. The subjects were divided into 2 groups: 1 group-CAD with positive coronary arteriography (n = 70), and the other group-CAD with negative coronary arteriography (n = 31). According to the anatomic localization of atherosclerotic lesion, the first group of subjects was divided into 1-vessel (n = 26), 2-vessel (n = 20), and multiple-vessel lesion (n = 24) subgroups, The results show a significant difference in Apo A, and Apo A(1)/Apo B (p < 0.005) in the 2- and multiple-vessel disease in relation to the control group, while subject significance was not proved for I-vessel disease. A positive correlation and significance for HDL as well as cholesterol ratio/HDL (p < 0.05) was noted for 1- and multiple-vessel disease, while a negative correlation was noted for 2-vessel disease in relation to the control group, This study stressed the diagnostic significance in determining Apo A(1) and Apo A(1)/Apo B-1 as better predictors than HDL cholesterol in evaluating coronary lesion severity. Dyslipoproteinemia, namely, the level of lipoproteins of low density, plays an important role in the pathogenesis of arteriosclerosis and the development of CAD.
引用
收藏
页码:557 / 562
页数:6
相关论文
共 50 条
  • [41] The biologist facing dyslipoproteinemia
    Duriez, P
    Fruchart, JC
    M S-MEDECINE SCIENCES, 1997, 13 (12): : 1396 - 1398
  • [42] Pathophysiological principles of dyslipoproteinemia
    Muller-Wieland, Dirk
    Merkel, Martin
    Verket, Marlo
    Marz, Winfried
    von Eckardstein, Arnold
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2021, 146 (22) : E103 - E111
  • [43] DYSLIPOPROTEINEMIA AND DIABETIC NEPHROPATHY
    SURANITI, S
    FRESSINAUD, P
    MARRE, M
    DIABETES & METABOLISM, 1991, 17 (02): : 308 - 312
  • [44] DYSLIPOPROTEINEMIA IN PRIMARY GOUT
    MERTZ, DP
    BABUCKE, G
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1973, 98 (31) : 1457 - 1462
  • [45] Drugs causing dyslipoproteinemia
    Donahoo, WT
    Kosmiski, LA
    Eckel, RH
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1998, 27 (03) : 677 - +
  • [47] DYSLIPOPROTEINEMIA IN PATIENTS WITH XANTHELASMA
    PINTO, X
    RIBERA, M
    FIOL, C
    ARCHIVES OF DERMATOLOGY, 1989, 125 (09) : 1281 - 1282
  • [48] GENETICALLY DETERMINED DYSLIPOPROTEINEMIA
    FREDRICKSON, DS
    CIRCULATION, 1976, 54 (04) : 2 - 2
  • [49] DYSLIPOPROTEINEMIA IN MANIFEST DIABETES
    MANZATO, E
    CREPALDI, G
    JOURNAL OF INTERNAL MEDICINE, 1994, 236 : 27 - 31
  • [50] Dyslipoproteinemia and physical activity
    Freiberger, V.
    Halle, M.
    DIABETOLOGE, 2012, 8 (07): : 562 - 567